EVOLVE-106

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameEVOLVE-106
Drug Alias NameEVOLVE-106
ClassificationBiologics > T cell engagers
Mechanisms of ActionAnti-CD2Anti-V-set domain-containing T-cell activation inhibitor 1
TargetsT-cell surface antigen CD2V-set domain-containing T-cell activation inhibitor 1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEvolveImmune Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesEvolveImmune Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A